CervoMed (CRVO) Competitors $8.51 -0.27 (-3.08%) Closing price 04:00 PM EasternExtended Trading$8.58 +0.07 (+0.82%) As of 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRVO vs. TRDA, CGC, IMMP, AURA, DBVT, HRTX, CMPX, ACB, ALMS, and CADLShould you be buying CervoMed stock or one of its competitors? The main competitors of CervoMed include Entrada Therapeutics (TRDA), Canopy Growth (CGC), Immutep (IMMP), Aura Biosciences (AURA), DBV Technologies (DBVT), Heron Therapeutics (HRTX), Compass Therapeutics (CMPX), Aurora Cannabis (ACB), Alumis (ALMS), and Candel Therapeutics (CADL). These companies are all part of the "pharmaceutical products" industry. CervoMed vs. Entrada Therapeutics Canopy Growth Immutep Aura Biosciences DBV Technologies Heron Therapeutics Compass Therapeutics Aurora Cannabis Alumis Candel Therapeutics CervoMed (NASDAQ:CRVO) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, community ranking, risk, earnings, profitability, analyst recommendations and valuation. Do institutionals & insiders hold more shares of CRVO or TRDA? 25.1% of CervoMed shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 35.4% of CervoMed shares are owned by company insiders. Comparatively, 7.6% of Entrada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, CRVO or TRDA? CervoMed has a beta of -0.23, suggesting that its share price is 123% less volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of 0.04, suggesting that its share price is 96% less volatile than the S&P 500. Which has preferable earnings & valuation, CRVO or TRDA? CervoMed has higher earnings, but lower revenue than Entrada Therapeutics. CervoMed is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCervoMed$7.14M10.37-$2.17M-$2.18-3.90Entrada Therapeutics$172.22M1.69-$6.68M$0.819.49 Is CRVO or TRDA more profitable? Entrada Therapeutics has a net margin of 25.53% compared to CervoMed's net margin of -118.68%. Entrada Therapeutics' return on equity of 16.11% beat CervoMed's return on equity.Company Net Margins Return on Equity Return on Assets CervoMed-118.68% -44.11% -39.81% Entrada Therapeutics 25.53%16.11%10.39% Does the MarketBeat Community believe in CRVO or TRDA? CervoMed received 3 more outperform votes than Entrada Therapeutics when rated by MarketBeat users. However, 84.62% of users gave Entrada Therapeutics an outperform vote while only 83.33% of users gave CervoMed an outperform vote. CompanyUnderperformOutperformCervoMedOutperform Votes2583.33% Underperform Votes516.67%Entrada TherapeuticsOutperform Votes2284.62% Underperform Votes415.38% Does the media prefer CRVO or TRDA? In the previous week, CervoMed had 5 more articles in the media than Entrada Therapeutics. MarketBeat recorded 14 mentions for CervoMed and 9 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 0.61 beat CervoMed's score of 0.24 indicating that Entrada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CervoMed 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Entrada Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend CRVO or TRDA? CervoMed currently has a consensus target price of $27.63, suggesting a potential upside of 224.62%. Entrada Therapeutics has a consensus target price of $25.67, suggesting a potential upside of 233.77%. Given Entrada Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Entrada Therapeutics is more favorable than CervoMed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CervoMed 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 2.89Entrada Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 SummaryEntrada Therapeutics beats CervoMed on 12 of the 19 factors compared between the two stocks. Get CervoMed News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRVO vs. The Competition Export to ExcelMetricCervoMedPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$74.06M$6.48B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E Ratio-3.908.9226.8419.71Price / Sales10.37250.96391.39116.98Price / CashN/A65.8538.2534.62Price / Book6.556.466.794.50Net Income-$2.17M$143.98M$3.23B$248.18M7 Day Performance2.28%3.04%4.07%1.14%1 Month Performance-8.49%7.44%12.52%15.20%1 Year Performance-56.22%-2.46%16.83%6.56% CervoMed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRVOCervoMed3.3449 of 5 stars$8.51-3.1%$27.63+224.6%-55.5%$74.06M$7.14M-3.904TRDAEntrada Therapeutics2.9644 of 5 stars$8.01-1.0%$25.67+220.4%-46.2%$304.00M$172.22M5.04110News CoverageAnalyst ForecastAnalyst RevisionCGCCanopy Growth1.4179 of 5 stars$1.64-1.2%$2.00+22.0%-82.5%$301.54M$276.75M-0.433,150IMMPImmutep1.5496 of 5 stars$2.04+0.5%$7.00+243.1%-35.2%$297.92M$5.14M0.002,021Gap DownAURAAura Biosciences2.4315 of 5 stars$5.92-0.5%$22.75+284.3%-16.5%$297.33MN/A-3.4250Earnings ReportInsider TradeGap UpDBVTDBV Technologies3.0148 of 5 stars$10.80-2.7%$15.50+43.5%+52.4%$295.81M$15.73M-2.4080Positive NewsGap UpHRTXHeron Therapeutics3.8862 of 5 stars$1.92-2.5%$5.50+186.5%-43.5%$292.92M$148.52M-10.67300CMPXCompass Therapeutics3.6966 of 5 stars$2.11+0.5%$13.13+522.0%+31.3%$291.78M$850,000.00-5.7020ACBAurora Cannabis0.6152 of 5 stars$5.02-2.1%N/A-27.8%$282.19M$320.81M100.421,340News CoverageALMSAlumis2.2013 of 5 stars$5.95+5.9%$24.86+317.8%N/A$280.97MN/A0.00N/AEarnings ReportTrading HaltedCADLCandel Therapeutics2.0294 of 5 stars$5.70+6.5%$21.00+268.4%-50.7%$280.84M$120,000.00-3.2960 Related Companies and Tools Related Companies TRDA Alternatives CGC Alternatives IMMP Alternatives AURA Alternatives DBVT Alternatives HRTX Alternatives CMPX Alternatives ACB Alternatives ALMS Alternatives CADL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRVO) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CervoMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CervoMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CRVO Stock Free CRVO Stock Alerts